悦心健康(002162) - 2020 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2020 was ¥121,471,485.59, a decrease of 35.36% compared to ¥187,927,447.05 in the same period last year[7] - The net profit attributable to shareholders was -¥19,076,892.88, representing a decline of 153.69% from -¥7,519,849.53 year-on-year[7] - The net cash flow from operating activities was -¥67,104,046.16, a significant drop of 558.94% compared to -¥10,183,642.94 in the previous year[7] - The company reported a weighted average return on equity of -1.97%, a decline of 1.16% compared to -0.81% in the previous year[7] - The net loss for the period was CNY 23,120,000, reflecting a significant decrease in profitability compared to the previous year[38] - The company's total profit for Q1 2020 was -¥20,389,800.85, compared to -¥7,253,694.69 in the same period last year[39] - The operating profit for Q1 2020 was -¥20,192,667.88, compared to -¥6,891,558.15 in the previous year, indicating a significant decline[39] - The net profit for Q1 2020 was a loss of ¥20,710,620.47, compared to a loss of ¥8,147,129.65 in the same period last year, representing an increase in loss of approximately 154.5%[40] Cash Flow - The net cash flow from operating activities was -67,104,046.16 CNY, compared to -10,183,642.94 CNY in the previous period, indicating a significant decline in operational cash flow[47] - Cash inflow from investment activities totaled 222,246,031.37 CNY, up from 142,473,342.89 CNY, while cash outflow for investments increased to 239,450,721.77 CNY from 182,550,456.52 CNY, resulting in a net cash flow from investment activities of -17,204,690.40 CNY, an improvement from -40,077,113.63 CNY[47] - The net cash flow from financing activities was 23,009,896.16 CNY, a recovery from -6,180,546.27 CNY in the previous period, driven by increased borrowings of 213,579,987.96 CNY compared to 168,580,000.00 CNY[48] - The cash outflow for operating activities was 115,045,443.15 CNY, a decrease from 122,781,237.85 CNY, leading to a net cash flow of 23,315,862.00 CNY, down from 53,961,626.66 CNY[50] - The company recorded a significant increase in cash received from investment recoveries, totaling 155,000,000.00 CNY, compared to 99,500,000.00 CNY in the previous period[51] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,308,120,869.63, down 1.38% from ¥2,340,351,166.84 at the end of the previous year[7] - The total assets as of March 31, 2020, were CNY 2.31 billion, a decrease from CNY 2.34 billion at the end of 2019[30] - Total liabilities amounted to CNY 1,347,767,676.46, with current liabilities at CNY 936,884,061.63 and non-current liabilities at CNY 410,883,614.83[55] - The company's equity attributable to shareholders was CNY 977,740,693.11, while total equity stood at CNY 992,583,490.38[55] - The company's total assets as of March 31, 2020, amounted to CNY 2,719,141,874.69, compared to CNY 2,640,592,119.01 at the end of 2019[34] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 53,959[11] - The basic and diluted earnings per share for Q1 2020 were both -¥0.0223, compared to -¥0.0088 in the previous year[40] Government Support - The company received government subsidies amounting to ¥1,504,361.73, primarily from the Shanghai government for business support[8] Other Financial Metrics - The company incurred financial expenses of ¥6,017,964.58 in Q1 2020, slightly down from ¥6,391,126.36 in the previous year[42] - The research and development expenses for Q1 2020 were ¥587,332.77, compared to ¥576,788.66 in the previous year, showing a slight increase[42] - The company reported other income of ¥499,603.40 in Q1 2020, compared to ¥434,032.00 in the previous year[42] Changes in Accounting Standards - The implementation of new revenue and leasing standards began in 2020, which may impact future financial reporting[59] Audit Status - The company has not yet audited its first-quarter report, which may affect the reliability of the financial data presented[60]